Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models
Author: Luo, K.
Ko, C.
Yue, G.
Lee, M.
Siu, W.
Lee, J.
Shum, W.
Fung, K.
Leung, P.
Li, G.
Evdokiou, A.
Lau, C.
Citation: Cancer Letters, 2013; 339(1):42-48
Publisher: Elsevier Sci Ireland Ltd
Issue Date: 2013
ISSN: 0304-3835
Statement of
Ke-Wang Luo, Chun-Hay Ko, Grace G.L. Yue, Michelle Y.Y. Lee, Wing-Sum Siu, Julia K.M. Lee, Wai-Ting Shum, Kwok-Pui Fung, Ping-Chung Leung, Gang Li, Andreas Evdokiou, Clara B.S. Lau
Abstract: This study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer.
Keywords: Zoledronic acid
Rights: Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
DOI: 10.1016/j.canlet.2013.07.024
Appears in Collections:Aurora harvest 4
Orthopaedics and Trauma publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.